PT-141
Acts on the brain to support desire and sexual function.
iThe essentials in 10 seconds
- Acts on the brain (melanocortin system) — not on blood vessels
- Increases desire and sexual response, in both women and men
- Subcutaneous injection, about 1 to 2 h before the desired moment
- On-demand use — possible transient nausea and blood pressure changes
IWhat is PT-141?
PT-141 (Bremelanotide) is a melanocortin receptor agonist: it acts on the central nervous system, on desire circuits, unlike conventional treatments that act on blood circulation. It is the 1st molecule of this type approved for female sexual desire disorder.
Regulated medication, with possible adverse effects (nausea, flushing, blood pressure). Reserved for prescription and medical monitoring, without uncontrolled cardiovascular risk factors.
The molecules presented on this site are innovative and fall under experimental use. Human data remain limited: a studied mechanism or a preclinical observation is not sufficient to demonstrate a benefit. The regulatory status in Morocco is not established for most of these peptides. Any use is decided within the framework of a medical consultation, with follow-up — never alone, never without an assessment.
IIThe benefits
Enhances sexual desire by acting on the brain's pleasure circuits.
Works on the brain, whereas conventional treatments act on blood flow.
Documented response in interest / sexual desire disorder (approved in Western countries).
May contribute to erectile response and desire as a complement to other approaches.
Effect within an hour after injection — on-demand use.
Combines with management of underlying causes (hormones, stress, medications).
IIIRecommendations & how to use
Route: subcutaneous injection (abdomen) · Timing: about 1 to 2 h before the desired moment · On-demand use, not daily · Storage: refrigerated (2–8 °C).
Avoid driving if nausea occurs.
| Dosage | Price |
|---|---|
| 10 mg | Provided on request |
Prices are not published online: they are provided on request, during a consultation or by telephone.
IVThe two protocols
Goal: improve desire and sexual response on an as-needed basis.
Monitoring: tolerability (nausea, blood pressure), perceived effect.
Goal: durably treat the causes of the disorder, as a complement to on-demand treatment.
Comprehensive approach: hormones, psychological factors, relationship, medications.
VProtocol rules
- Contextualize: desire remains largely psychological and relational
- Sleep and stress management
- Hormonal workup in parallel
- Note effect and tolerability
- Store vials in the refrigerator
- Never self-medicate: prescription medication
- Do not exceed the prescribed dose
- Driving if nausea after injection
- Excess alcohol on the day of use
- Uncontrolled hypertension or cardiovascular disease, pregnancy: contraindication
VIYour journey in 3 steps
Assessment (hormones, blood pressure, medications), injection training, protocol provided.
Injection 1 to 2 h before the desired moment, monitoring tolerability.
Efficacy, tolerability, decision on continuation and background treatment.
VIISide effects & level of evidence
- Nausea, vomiting
- Flushing
- Headache
- Transient blood-pressure rise
- Hyperpigmentation (repeated use)
- Uncontrolled hypertension
- Known cardiovascular disease
- Concurrent oral naltrexone
- Pregnancy; hypersensitivity
Non-exhaustive list based on the available literature and known class effects; it replaces neither a product label nor an individual medical assessment.
VIIIPublications & references
- Bremelanotide · · 2012 · PMID 34436837
- Bremelanotide · · 2006 · PMID 31369224
- Bremelanotide: First ApprovalDhillon S, Keam SJ · Drugs · 2019 · PMID 31429064
Documentary references: the existence of a publication establishes neither efficacy nor safety for personal use. The regulatory status in Morocco must be verified.